|
KMID : 1137020220330040055
|
|
Journal of Gynecologic Oncology
2022 Volume.33 No. 4 p.55 ~ p.55
|
|
|
Phase II study of niraparib in recurrent or persistent rare fraction of gynecologic malignancies with homologous recombination deficiency (JGOG2052)
|
|
Asano Hiroshi
Oda Katsutoshi
Yoshihara Kosuke
Ito Yoichi M.
Matsumura Noriomi
Shimada Muneaki
Watari Hidemichi
Enomoto Takayuki
|
|
|
Abstract
|
|
|
Background: Poly (adenosine diphosphate)-ribose polymerase (PARP) inhibitors for tumors with homologous recombination deficiency (HRD), including pathogenic mutations in BRCA1/2, have been developed. Genomic analysis revealed that about 20% of uterine leiomyosarcoma (uLMS) have HRD, including 7.5%?10% of BRCA1/2 alterations and 4%?6% of carcinomas of the uterine corpus, and 2.5%?4% of the uterine cervix have alterations of BRCA1/2. Preclinical and clinical case reports suggest that PARP inhibitors may be effective against those targets. The Japanese Gynecologic Oncology Group (JGOG) is now planning to conduct a new investigator-initiated clinical trial, JGOG2052.
Methods: JGOG2052 is a single-arm, open-label, multi-center, phase 2 clinical trial to evaluate the efficacy and safety of niraparib monotherapy for a recurrent or persistent rare fraction of gynecologic malignancies with BRCA1/2 mutations except for ovarian cancers. We will independently consider the effect of niraparib for uLMS or other gynecologic malignancies with BRCA1/2 mutations (cohort A, C) and HRD positive uLMS without BRCA1/2 mutations (cohort B). Participants must have 1?3 lines of previous chemotherapy and at least one measurable lesion according to RECIST (v.1.1). Niraparib will be orally administered once a day until lesion exacerbation or unacceptable adverse events occur. Efficacy will be evaluated by imaging through an additional computed tomography scan every 8 weeks. Safety will be measured weekly in cycle 1 and every 4 weeks after cycle 2 by blood tests and physical examinations. The sample size is 16?20 in each of cohort A and B, and 31 in cohort C. Primary endpoint is the objective response rate.
|
|
|
KEYWORD
|
|
|
Gynecologic Neoplasms, Leiomyosarcoma, Homologous Recombination Repair, Gene, Mutation, Poly(ADP-ribose) Polymerase Inhibitors
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
    
|
|